ML 281STK33 inhibitor CAS# 1404437-62-2 |
- BMN-673 8R,9S
Catalog No.:BCC1422
CAS No.:1207456-00-5
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- PJ34
Catalog No.:BCC1865
CAS No.:344458-19-1
- ABT-888 (Veliparib)
Catalog No.:BCC1267
CAS No.:912444-00-9
- Veliparib dihydrochloride
Catalog No.:BCC2076
CAS No.:912445-05-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1404437-62-2 | SDF | Download SDF |
| PubChem ID | 53377448 | Appearance | Powder |
| Formula | C22H19N3O2S | M.Wt | 389.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 30 mg/mL (77.03 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[2-(3-oxo-4H-quinoxalin-2-yl)-4-propan-2-ylphenyl]thiophene-2-carboxamide | ||
| SMILES | CC(C)C1=CC(=C(C=C1)NC(=O)C2=CC=CS2)C3=NC4=CC=CC=C4NC3=O | ||
| Standard InChIKey | HWOYIOLMBQSTQS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H19N3O2S/c1-13(2)14-9-10-16(24-21(26)19-8-5-11-28-19)15(12-14)20-22(27)25-18-7-4-3-6-17(18)23-20/h3-13H,1-2H3,(H,24,26)(H,25,27) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Inhibitor of the serine/threonine kinase STK33 (IC50 = 14 nM). Exhibits >700-fold selectivity for STK33 over the structurally related protein kinase A (PKA); also exhibits 550-fold selectivity over Aurora kinase B. |
ML 281 Dilution Calculator
ML 281 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5676 mL | 12.838 mL | 25.6759 mL | 51.3518 mL | 64.1898 mL |
| 5 mM | 0.5135 mL | 2.5676 mL | 5.1352 mL | 10.2704 mL | 12.838 mL |
| 10 mM | 0.2568 mL | 1.2838 mL | 2.5676 mL | 5.1352 mL | 6.419 mL |
| 50 mM | 0.0514 mL | 0.2568 mL | 0.5135 mL | 1.027 mL | 1.2838 mL |
| 100 mM | 0.0257 mL | 0.1284 mL | 0.2568 mL | 0.5135 mL | 0.6419 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM. ML281 showed a 550-fold selectivity over AurB and greater than 700-fold selectivity over PKA. target: STK33 IC50: 14 nM [1] ML281 showed low nanomolar inhibition of purified recombinant STK33 and a distinct selectivity profile as compared to other STK33 inhibitors. Even at the highest concentration tested (10 μM), ML281 had no effect on the viability of KRAS-dependent cancer cells. [2]
References:
[1]. We?wer M et al. A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett, 2012 Dec 13, 3(12):1034-1038.
[2]. Spoonamore J et al. Screen for Inhibitors of STK33 Kinase Activity. National Center for Biotechnology Information (US); 2010-2011 Dec 16.
- Fmoc-Dap(Dnp)-OH
Catalog No.:BCC2666
CAS No.:140430-54-2
- 7-Methoxycoumarin-4-acetyl-P-L-G-L-β-(2,4-dinitrophenylamino)A-R amide
Catalog No.:BCC1086
CAS No.:140430-53-1
- ON 146040
Catalog No.:BCC8058
CAS No.:1404231-34-0
- CCT244747
Catalog No.:BCC6423
CAS No.:1404095-34-6
- RSVA 405
Catalog No.:BCC8016
CAS No.:140405-36-3
- Vancomycin hydrochloride
Catalog No.:BCC4232
CAS No.:1404-93-9
- 6'-O-Cinnamoyl-8-epikingisidic acid
Catalog No.:BCN7059
CAS No.:1403984-03-1
- Nexturastat A
Catalog No.:BCC5345
CAS No.:1403783-31-2
- PFI-1 (PF-6405761)
Catalog No.:BCC2225
CAS No.:1403764-72-6
- Heteroclitin D
Catalog No.:BCN8166
CAS No.:140369-76-2
- Macranthoidin A
Catalog No.:BCN2808
CAS No.:140360-29-8
- EPZ-6438
Catalog No.:BCC3634
CAS No.:1403254-99-8
- GSK 2830371
Catalog No.:BCC4179
CAS No.:1404456-53-6
- 11-Hydroxyjasmonic acid
Catalog No.:BCN6221
CAS No.:140447-14-9
- Ergosterol peroxide glucoside
Catalog No.:BCN6222
CAS No.:140447-22-9
- Heteroclitin C
Catalog No.:BCN3632
CAS No.:140460-42-0
- Heteroclitin B
Catalog No.:BCN3745
CAS No.:140461-47-8
- Olopatadine HCl
Catalog No.:BCC4545
CAS No.:140462-76-6
- Neomycin sulfate
Catalog No.:BCC4682
CAS No.:1405-10-3
- Capreomycin Sulfate
Catalog No.:BCC4644
CAS No.:1405-37-4
- Gentamycin Sulfate
Catalog No.:BCC1203
CAS No.:1405-41-0
- Tylosin phosphate
Catalog No.:BCC5551
CAS No.:1405-53-4
- Glycyrrhizic acid
Catalog No.:BCN5941
CAS No.:1405-86-3
- Bacitracin
Catalog No.:BCC4632
CAS No.:1405-87-4
A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells.[Pubmed:23256033]
ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
The KRAS oncogene is found in up to 30% of all human tumors. In 2009, RNAi experiments revealed that lowering mRNA levels of a transcript encoding the serine/threonine kinase STK33 was selectively toxic to KRAS-dependent cancer cell lines, suggesting that small-molecule inhibitors of STK33 might selectively target KRAS-dependent cancers. To test this hypothesis, we initiated a high-throughput screen using compounds in the Molecular Libraries Small Molecule Repository (MLSMR). Several hits were identified, and one of these, a quinoxalinone derivative, was optimized. Extensive SAR studies were performed and led to the chemical probe ML281 that showed low nanomolar inhibition of purified recombinant STK33 and a distinct selectivity profile as compared to other STK33 inhibitors that were reported in the course of these studies. Even at the highest concentration tested (10 muM), ML281 had no effect on the viability of KRAS-dependent cancer cells. These results are consistent with other recent reports using small-molecule STK33 inhibitors. Small molecules having different chemical structures and kinase-selectivity profiles are needed to fully understand the role of STK33 in KRAS-dependent cancers. In this regard, ML281 is a valuable addition to small-molecule probes of STK33.
